Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a basel...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Psychiatry |
| Online Access: | http://dx.doi.org/10.1155/2022/3684181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554733345177600 |
|---|---|
| author | Vikas Thanvi |
| author_facet | Vikas Thanvi |
| author_sort | Vikas Thanvi |
| collection | DOAJ |
| description | Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD. |
| format | Article |
| id | doaj-art-c9606930e58e44a29abd46ebd422483d |
| institution | Kabale University |
| issn | 2090-6838 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Psychiatry |
| spelling | doaj-art-c9606930e58e44a29abd46ebd422483d2025-02-03T05:50:41ZengWileyCase Reports in Psychiatry2090-68382022-01-01202210.1155/2022/3684181Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic SymptomsVikas Thanvi0Dr. Thanvi’s Neuropsychiatry and Psychotherapy CentreEvidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD.http://dx.doi.org/10.1155/2022/3684181 |
| spellingShingle | Vikas Thanvi Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms Case Reports in Psychiatry |
| title | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
| title_full | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
| title_fullStr | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
| title_full_unstemmed | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
| title_short | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
| title_sort | real world long term experience on endoxifen in bipolar disorder with psychotic symptoms |
| url | http://dx.doi.org/10.1155/2022/3684181 |
| work_keys_str_mv | AT vikasthanvi realworldlongtermexperienceonendoxifeninbipolardisorderwithpsychoticsymptoms |